pipeline

Our pipeline for the continuous benefit to patients

TG-C is a non-surgical treatment cell-mediated gene therapy for osteoarthritis, which is the most common form of arthritis. A first-in-class cell and gene therapy, TG-C targets knee osteoarthritis through a single intra-articular injection.  

*The exact therapeutic indication and registration status may be different in each country. Please consult the official approved product information in your country. 

TRUSELTIQ® (infigratinib) capsules 25mg/100mg is indicated for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. TRUSELTIQ®  is a pipeline therapy which has already been approved for 2nd Line with Phase 3 Trials and is currently under investigation as a potential first-line treatment for individuals with Adjuvant Urothelial Cancer in Australia.

*The exact therapeutic indication and registration status may be different in each country. Please consult the official approved product information in your country.